Glenmark Pharmaceuticals Ltd. (India) has announced that its European organisation, acting through its Czech subsidiary Medicamenta, has signed agreements with Actavis, the international generic pharmaceutical company from Iceland, and Biovena (an affiliate of Actavis in Poland) to acquire 7 pharmaceutical brands in Poland with effect from July 1, 2008. The acquisition of the products from these two different companies for an undisclosed sum will provide Glenmark its first access to the growing Polish market, the largest pharmaceutical market in Central & East Europe.
The details can be read here.
No comments:
Post a Comment